It is a major setback for Novo Nordisk in the battle for control of the market for long-acting insulin that Tresiba is not set to hit the US market for some time to come now, Novo’s Chief Science Officer, Mads Krogsgaard Thomsen, admits to Medwatch.
“It is a strain for us as far as basal insulin is concerned, we have to admit. Tresiba is approved in Japan, Europe and Mexico, but not on the single largest market in the world – the US market. We are not in the lead there, Sanofi is with Lantus, and Tresiba was set to usurp that pole position. But it is not right around the next bend anymore and we are obviously annoyed and disappointed about it,” he says.